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ABSTRACT 46 
Background: 47 
Psoriasis is a common inflammatory skin disease that has been reported to be associated with obesity. 48 
We aimed to investigate a possible causal relationship between body mass index (BMI) and psoriasis. 49 
  50 
Methods and Findings: 51 
Following a review of published epidemiological evidence of the association between obesity and 52 
psoriasis, Mendelian Randomization (MR) was used to test for a causal relationship with BMI. We used 53 
a genetic instrument comprising 97 single nucleotide polymorphisms (SNPs) associated with BMI, as a 54 
proxy for BMI (expected to be much less confounded than measured BMI). One-sample MR was 55 
conducted using individual-level data (396,495 individuals) from the UK Biobank and the Nord-56 
Trøndelag Health Study (HUNT), Norway. Two-sample MR was performed with summary-level data 57 
(356,926 individuals) from published BMI and psoriasis GWAS studies. The one-sample and two-58 
sample MR estimates were meta-analysed using a fixed effect model. To test for a potential reverse 59 
causal effect, MR analysis with genetic instruments comprising variants from recent genome-wide 60 
analyses for psoriasis were used to test if genetic risk for this skin disease has a causal effect on BMI. 61 
Published observational data showed an association of higher BMI with psoriasis. A mean difference 62 
in BMI of 1.26 kg/m2 (95% CI 1.02 to 1.51) between psoriasis cases and controls was observed in 63 
adults, while a 1.55 kg/m2 mean difference (95% CI 1.13 to 1.98) was observed in children. The 64 
observational association was confirmed in UK Biobank and HUNT datasets. Overall, 1 kg/m2 65 
increase in BMI was associated with 4% higher odds of psoriasis (meta-analysis OR=1.04; 95% CI 1.03 66 
to 1.04; P=1.73x10-60). MR analyses provided evidence that higher BMI causally increases the odds of 67 
psoriasis (by 9% per 1 unit increase in BMI; OR= 1.09 (1.06 to 1.12) per 1 kg/m2; P=4.67x10-9). In 68 
contrast, MR estimates gave no evidence to support a causal effect of psoriasis genetic risk on BMI, 69 
(0.01 kg/m2 change in BMI per doubling odds of psoriasis (-0.01 to 0.03). Limitations of our study 70 
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include possible misreporting of psoriasis by patients, and potential misdiagnosis by clinicians. In 71 
addition, there is also limited ethnic variation in the cohorts studied. 72 
 73 
Conclusions: 74 
Our study, using genetic variants as instrumental variables for BMI, provides evidence that higher BMI 75 
leads to a higher risk of psoriasis. This supports the prioritisation of therapies and life-style 76 
interventions aimed at controlling weight for the prevention or treatment of this common skin 77 
disease. Mechanistic studies are required to improve understanding of this relationship. 78 
 79 
AUTHOR SUMMARY 80 
Why was this study done? 81 
 Psoriasis is a common inflammatory skin disease that has been reported to be associated 82 
with obesity. However, the direction of causality has not been established. 83 
 Understanding the causal relationship could inform the management or prevention of 84 
disease. 85 
What did the researchers do and find? 86 
 A Mendelian Randomization approach was used to investigate the causal relationship 87 
between higher BMI and psoriasis. 88 
 Our analysis included data for a total of 753,421 individuals from two of the largest 89 
population-based studies available as well as published GWAS studies.  90 
 We found evidence that higher BMI causally increases the risk of psoriasis, supporting 91 
observational reports in previous literature.  92 
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 Conversely, there was no evidence to support a causal effect of psoriasis genetic risk upon 93 
BMI.  94 
 95 
What do these findings mean? 96 
 Our findings suggest a possible mechanism where obesity contributes to the pathogenesis of 97 
psoriasis. 98 
 If our findings regarding genetically influenced BMI can be extended to elevated BMI that is 99 
amenable to modification by diet or behaviour, then they could carry health implications.  100 
 Further work will be required to determine the effect of a short-term intervention aimed at 101 
reducing BMI upon psoriasis patients after disease onset, ideally within a clinical trial setting.  102 
 103 
 104 
INTRODUCTION 105 
Psoriasis is a common inflammatory skin disorder that is characterised by erythematous scaly plaques; 106 
severe disease is associated with significant impairment in physical and mental health [1]. Psoriasis 107 
affects approximately 2% of people within European populations [2], with higher prevalence estimates 108 
in Northern regions of Europe [3].  109 
The prevalence of disease has also been found to be increasing [4]. Obesity has become one of the 110 
leading health issues of the 21st century with over one quarter of the UK population now obese, and 111 
similarly high obesity levels in many other parts of the world [5]. In addition to clear links of obesity to 112 
diabetes and hypertension, observational evidence from epidemiological studies have suggested a 113 
relationship of increased weight with psoriasis [6]. Furthermore, a small number of weight loss 114 
interventions have been shown to improve psoriasis and increase responsiveness to treatment [7–9]. 115 
Hypothetically, obesity could promote skin inflammation, or vice versa [10], but skin disease can also 116 
lead to a reduced participation in physical activity, resulting in weight gain. A clearer understanding of 117 
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the cutaneous and systemic metabolic effects associated with obesity and psoriasis is an essential 118 
prerequisite to define treatment and prevention strategies for these prevalent public health issues. 119 
  120 
Causality can be investigated with Mendelian Randomization (MR), which uses genetic variants to 121 
randomly allocate individuals to groups based on genotype (analogous to a randomised trial) [11]. At 122 
conception, genetic variants are randomly allocated from parents to offspring. Therefore, 123 
confounding and reverse causation, common limitations of observational studies, can be avoided by 124 
using genetic variants as instrumental variables to estimate the causal effect of a risk factor upon an 125 
outcome of interest [11–13]. Genome-wide association studies (GWAS) of BMI in the GIANT 126 
consortium have identified 97 loci (accounting for 2.7% of the variance of this trait) and made full 127 
summary statistics available [14] (a recent study has increased this to 716 loci, explaining 5.0% of the 128 
variance [15]). GWAS summary statistics for psoriasis are also available, for which 63 risk loci have 129 
been identified [16]. This work has provided powerful data with which to perform MR [12].  130 
 131 
In this study, we first reviewed the literature reporting observational evidence for associations 132 
between BMI and psoriasis and extended the observational associations in two large population-133 
based studies. We then applied MR to test for evidence of causality, strength of association and the 134 
direction of causality between BMI with psoriasis. 135 
 136 
METHODS 137 
Literature review and meta-analysis 138 
We searched for published studies that compare the weight or overweight or obesity rates between 139 
individuals with psoriasis and healthy controls. All studies identified in a PubMed search were 140 
considered for review. PubMed was searched on 08/07/2016 with the terms “psoriasis AND (obesity 141 
OR overweight OR BMI)”. The inclusion criteria were: an operationalised definition of psoriasis (any 142 
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definition was accepted, including psoriatic arthritis); inclusion of cases meeting this definition of 143 
psoriasis plus a control group without psoriasis; and presentation of data for a BMI-related trait within 144 
the psoriasis and control groups. Studies were excluded if they did not present data for both groups; 145 
if they did not present usable data in the paper; if they matched individuals with psoriasis and controls 146 
on BMI, or if cases and controls were both drawn from a disease subpopulation. We did not exclude 147 
studies where participants may have incidental comorbidities. We extracted the location of the study, 148 
the study name (if applicable), age of the study population, features of the control group (for example 149 
if they were drawn from another dermatological population), the type of study, how psoriasis was 150 
determined (if it was current, recent, or lifetime disease), the covariates used in the analysis, and the 151 
definition of overweight and obesity used by the study. All data pertaining to weight and psoriasis 152 
were extracted and a meta-analysis was performed of the definition with the most available data 153 
(mean difference in BMI between cases and controls). The following formula was used to obtain an 154 
approximate odds ratio (OR) of the effect of BMI on psoriasis, as previously demonstrated by Perry et 155 
al [17]: 156 
OR = exp(1.81 x (SD x SMD)) 157 
Where SD is the standard deviation increase in BMI per standard deviation change in the BMI genetic 158 
instrument (genetic risk score); SMD is the standardised mean difference and 1.81 is the scaling factor 159 
used to convert standardised mean differences to ln(ORs) [18,19] (see Supporting Text 1 in S1 160 
Appendix). 161 
The meta-analysis was conducted separately for children and adults, as well as combined. A random 162 
effects model was used due to the inclusion of heterogeneous populations and study designs being 163 
meta-analysed. Egger regression was also performed to detect the presence of publication bias. 164 
  165 
Investigating causal relationships: 166 
Study populations 167 
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Data were available, for a total of 396,495 participants including 5,676 psoriasis cases from the UK 168 
Biobank, aged between 40-69 years [20] and 1,076 psoriasis cases from the third survey of the Nord-169 
Trøndelag Health Study (HUNT, 2006-08), aged 20 years and over [21] (Table 1). All individuals 170 
included were of European ancestry and had provided written informed consent. UK Biobank has 171 
received ethics approval from the National Health Service National Research Ethics Service (ref 172 
11/NW/0382; UK Biobank application number 10074). The HUNT Study was approved by the Regional 173 
Committee for Medical and Health Research Ethics (REC Central). Approval was also received from the 174 
Regional Committee for Medical and Health Research Ethics in Mid-Norway (2015/586, 2015/2003). 175 
 176 
Table 1: Descriptive statistics of datasets used in the study 177 
  178 
Dataset 
Sample 
size 
Psoriasis cases/controls       
(% of cases) 
Females (%) 
Mean [SD] 
age (years) 
Mean [SD] 
BMI (kg/m2) 
UK Biobank 378,274 5,676 / 372,598 (1.5%) 203,912 (53.9%) 57.2 [8.0] 27.4 [4.8] 
HUNT 18,221 1,076 / 17,145 (5.8%) 10,076 (55.3%) 53.7 [15.2] 27.2 [4.4] 
BMI 
GWAS[14] 
322,154 - - - 27.1 [4.6] 
Psoriasis 
GWAS[16] 
34,772 13,229 / 21,543 (38.0%) - - - 
BMI=body mass index; HUNT=the Nord-Trøndelag Health Study; SD=standard deviation 179 
 180 
 181 
 Summary level data were also available for 356,926 individuals of European ancestry from published 182 
GWAS studies for BMI [14] (n=322,154) and psoriasis [16] (n=34,772).   183 
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 184 
Clinical outcomes 185 
The BMI of UK Biobank participants was calculated from standing height and weight measurements 186 
that were taken while visiting an assessment centre. Units of BMI are kg/m2. Individuals were defined 187 
as having psoriasis based on their response during a verbal interview with a trained member of staff 188 
at the assessment centre. Participants were asked to tell the interviewer which serious illnesses or 189 
disabilities they had been diagnosed with by a doctor and were defined as psoriasis cases if this disease 190 
was mentioned. Disease information was also obtained from the Hospital Episode Statistics (HES) data 191 
extract service where health-related outcomes had been defined by International Classification of 192 
Diseases (ICD)-10 codes (see Table 1 in S1 Appendix). 193 
  194 
 Within HUNT participants’ height and weight were measured and used to calculate BMI (kg/m2). 195 
Participants were defined as psoriasis cases based on their response to a general questionnaire sent 196 
to all HUNT participants. Psoriasis cases responded affirmatively to the question “Have you had or do 197 
you have psoriasis?”. The diagnostic properties of the psoriasis question have been validated in HUNT 198 
(positive predictive value was 78%; 95% CI 69 to 85) [22]. 199 
Genotyping 200 
Genotyping of UK Biobank participants was performed with one of two arrays (The Applied 201 
BiosystemsTM UK BiLEVE AxiomTM Array (Affymetrix) and Applied BiosystemsTM UK Biobank AxiomTM 202 
Array). Sample quality control (QC) measures included removing individuals who were duplicated and 203 
highly related (3rd degree or closer), had sex mismatches, as well as those identified to be outliers of 204 
heterozygosity and of non-European descent. Further details of the QC measures applied and 205 
imputation performed have been described previously [23–26]. 206 
 Genotyping of the HUNT participants was performed with one of three different Illumina 207 
HumanCoreExome arrays (HumanCoreExome12 v1.0, HumanCoreExome12 v1.1 and UM HUNT 208 
10 
 
Biobank v1.0). The genotypes from different arrays had QC performed separately and were reduced 209 
to a common set of variants across all arrays. Sample QC measures were similar to those applied to 210 
the UK Biobank. Related individuals were excluded from the analysis(n=30,256). Details of the 211 
genotyping, QC measures applied and imputation have been described elsewhere [27]. 212 
  213 
Confounder variables 214 
Within UK Biobank, confounders that were considered in the current study were age, sex, smoking 215 
status, alcohol intake and educational attainment. The age and sex of participants were baseline 216 
characteristics determined at recruitment. The information on age was coded and analysed as a 217 
continuous variable, while sex was analysed as a binary variable.  218 
Smoking status, alcohol intake and educational attainment were defined by responses to a 219 
touchscreen questionnaire. The smoking status of participants was summarised as being a current or 220 
previous smoker, or never smoked, where this information was coded into a categorical variable. 221 
Alcohol intake frequency was determined by asking participants “about how often do you drink 222 
alcohol?”, where options included “Daily or almost daily”, “Three or four times a week”, “One to three 223 
times a month”, “Special occasions only” and “Never”. This information was categorised for daily, 224 
weekly and monthly alcohol intake. Educational attainment was also defined by asking “which of the 225 
following qualifications do you have?”, where participants could select more than one option including 226 
“College or University degree”, “A levels/AS levels or equivalent”, “O levels/GCSEs or equivalent”, 227 
“CESs or equivalent”, “NVQ or HND or HNC or equivalent”, “Other professional qualifications eg: 228 
nursing, teaching”, or “None of the above”. Participant responses were coded into categorical 229 
variables for degree holders, and those who had completed advanced level studies (A-level) or had 230 
obtained their general certificate of secondary education (GCSE).   231 
  232 
11 
 
Within HUNT, confounders considered in the current study were age, sex, smoking status and alcohol 233 
intake. Information on educational attainment was not available in the third survey of the HUNT study. 234 
The age and sex of participants were determined at the time of participation. The information on age 235 
was coded and analysed as a continuous variable, while sex was analysed as a binary variable. 236 
Smoking status and alcohol intake were defined by the participants response to a questionnaire. 237 
Smoking status was defined as being never, former, occasional, or current smoker. Alcohol intake 238 
frequency was determined by asking participants “about how often in the last 12 months did you drink 239 
alcohol?”, where options included “4-7 times a week”, “2-3 times a week”, “about once a month”, “a 240 
few times a year”, “not at all last year” and “never drunk alcohol”.    241 
 242 
Observational analysis 243 
Within the UK Biobank and HUNT datasets, logistic regression models were used to estimate the 244 
observational association between BMI and psoriasis. Analyses were adjusted for age, sex, smoking 245 
status, alcohol intake and educational attainment (where information was available in UK Biobank 246 
only). The estimates for each dataset were meta-analysed assuming a fixed effect model. 247 
  248 
Defining genetic instruments 249 
The genetic instrument for BMI comprised the 97 BMI associated SNPs reported by the GIANT 250 
consortium to account for approximately 2.7% of BMI variation (a meta-analysis of 125 GWAS studies 251 
with 339,224 individuals) [14]. These SNPs were extracted from both the UK Biobank and HUNT 252 
datasets (see Table 2 and Table 3 in S1 Appendix) to perform one-sample MR analysis in each dataset. 253 
We also combined these SNPs to create a standardised genetic risk score (GRS) using the --score 254 
command in PLINK (version 1.9). In doing so the dosage of the effect allele for each SNP was weighted 255 
by the effect estimates reported for the European sex-combined analysis (n= 322,154) by Locke et al 256 
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[14], summed across all variants, and divided by the total number of variants. The scores were 257 
standardized to have a mean of 0 and standard deviation of 1. 258 
The BMI-associated SNP rs12016871 was not present within the UK Biobank and HUNT datasets, 259 
therefore rs9581854 was used as a highly correlated proxy (r2 = 1.0) (see Table 4 in S1 Appendix). 260 
The BMI associated SNPs most recently reported by Yengo et al [15] were also used as an updated 261 
genetic instrument for BMI. 262 
  263 
For the psoriasis genetic instrument, 62 psoriasis associated SNPs (outside of the human leukocyte 264 
antigen (HLA) region) were obtained from the most recent psoriasis GWAS study (a meta-analysis of 265 
13,229 cases and 21,543 controls of European ancestry) [16]. These SNPs were extracted from both 266 
the UK Biobank and HUNT datasets and used as instruments to perform one-sample MR analysis in 267 
each dataset. These SNPs were also combined to create a standardised GRS, where they were 268 
weighted by their published effect sizes. The psoriasis-associated SNP rs118086960 was not present 269 
in the UK Biobank or HUNT datasets and had no suitable proxy (r2 > 0.8). Therefore 61 independent 270 
SNP associations were used as a genetic instrument to perform the one-sample MR analysis (see Table 271 
5 and Table 6 in S1 Appendix).  272 
 The reported BMI associated SNPs and psoriasis associated SNPs were also used to perform two-273 
sample MR analysis, using summary data from the published GWAS study for each trait [14,16]. 274 
  275 
Mendelian Randomization analysis 276 
One-sample MR analysis was performed separately in UK Biobank and also the HUNT dataset, using 277 
individual-level data with participants’ BMI SNPs, measured BMI and disease outcome status (Fig 1). 278 
The MR estimates from each genetic instrument (SNP) were meta-analysed assuming a random effects 279 
model, giving a single estimate for the analysis performed in each dataset. A random effects model 280 
was used here, to avoid over-precision of the causal estimate, and to allow for heterogeneity in the 281 
causal estimates being meta-analysed from the different genetic variants.  282 
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The MR analysis with the individual BMI SNPs was performed with the two-stage predictor 283 
substitution (TSPS) method [28]. The first stage involved regression of BMI upon individual BMI SNPs. 284 
The outcome (psoriasis) was then regressed upon the fitted values from the first regression stage. As 285 
psoriasis is a binary outcome, the first stage linear regression was restricted to individuals that were 286 
controls for psoriasis only, as recommended by Burgess et al [29]. Logistic regression was then 287 
performed in the second stage where the fitted values for the cases were predicted. The standard 288 
errors (SE) of these estimates were adjusted using the first term of the delta method expansion for 289 
the variance of a ratio, allowing for the uncertainty in the first regression stage to be taken into 290 
account [29]. 291 
Genetic principal components (as previously described [25–27]) were included as covariates in the 292 
analysis to control for residual population structure. UK Biobank analysis also controlled for the 293 
platform used to genotype the samples. In the HUNT dataset the genotyped data were reduced to a 294 
common set of variants across all platforms before imputation. 295 
Two-sample MR analysis of published GWAS data was performed using the 296 
“MendelianRandomisation” R package [30,31]. Estimates for the association between BMI and BMI 297 
SNPs in Europeans were taken from the GIANT BMI GWAS study published by Locke and colleagues 298 
[14]. Summary statistics from the most recent psoriasis [16] GWAS studies were used to obtain 299 
estimates for the association of psoriasis with the BMI SNPs in Europeans. The published BMI SNP 300 
estimates were based on an inverse normal transformation of BMI residuals on age and age2, as well 301 
as any necessary study-specific covariates. In unrelated individuals, residuals were calculated 302 
according to sex and case/control status, and were sex-adjusted amongst related individuals [14]. 303 
Therefore the causal estimates for the two-sample analysis were converted to raw BMI units (kg/m2), 304 
assuming a median BMI standard deviation of 4.6 kg/m2 [14]. 305 
The one and two-sample estimates were meta-analysed assuming a fixed effect model to obtain an 306 
overall causal estimate, assuming no between-method heterogeneity.  307 
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An additional two-sample MR analysis was performed in the same manner, using BMI SNP-BMI 308 
association estimates from the more recent BMI meta-analysis by Yengo and colleagues, where 716 309 
SNPs had been reported to account for approximately 5% of the variance of BMI [15]. 310 
  311 
 312 
  313 
  314 
Fig 1.  Schematic representation of MR analyses. a) BMI SNPs were used as instrumental variables to 315 
investigate the causal effect of BMI upon psoriasis. b) Psoriasis SNPs were used as instrumental 316 
variables to investigate the causal effect of genetic risk of psoriasis upon BMI. Arrows indicate MR 317 
assumption where the instrumental variable is associated with the exposure, not associated with 318 
confounders, and only affects the outcome via the exposure. 319 
BMI= body mass index; SNP=single nucleotide polymorphism. 320 
   321 
Sensitivity analysis 322 
MR-Egger regression, weighted median analysis and the weighted mode-based estimate (MBE) were 323 
used to investigate potential pleiotropy. SNPs that act through a pleiotropic pathway would violate 324 
the MR assumption that the instrumental variable has an effect upon the outcome only via the 325 
exposure being investigated, and could bias the causal estimate. The weighted median method 326 
provides a valid causal estimate if at least 50% of the information each instrument contributes to the 327 
analysis comes from valid instruments [32]. Likewise, the weighted MBE also provides a valid causal 328 
estimate if the largest weights are from valid instruments [33], whilst the intercept from the MR-Egger 329 
regression analysis allows the size of any pleiotropic effect to be determined [34]. MR-Egger regression 330 
gives a valid causal estimate under the InSIDE assumption, where each SNP-exposure association is 331 
independent of the direct pleiotropic effect of the SNP [34]. 332 
In addition, one-sample MR analysis was performed using the FTO SNP alone (rs1558902) as a genetic 333 
instrument due to its strong association with BMI [35]. 334 
As the instrumental variables used in an MR analysis are assumed to be independent of confounders, 335 
we investigated the relationship between the BMI GRS and potential confounders of BMI by 336 
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performing a simple regression of the confounder upon the BMI GRS. The relationship between the 337 
FTO variant and potential confounders were also investigated. 338 
  339 
Reverse direction MR analysis 340 
We also investigated the causal effect of the genetic liability of psoriasis upon BMI (Fig 1). One-sample 341 
MR analysis was performed in UK Biobank and also in the HUNT dataset with the two-staged least 342 
squares (TSLS) method, where psoriasis-associated SNPs were used as instruments. As with the TSPS 343 
method, this analysis involves two regression stages. Psoriasis was regressed upon the psoriasis 344 
genetic instrument, the outcome (BMI) was then regressed upon the fitted values from the first stage 345 
regression. The one-sample MR estimates from each dataset were then meta-analysed assuming a 346 
fixed effect model to give a single causal estimate (change in BMI per log odds of psoriasis). In addition, 347 
one-sample MR analysis was also performed where the exposure (genetic liability of psoriasis) was 348 
considered as a linear variable with values from “0” to “1” to aid interpretation of the causal estimate 349 
(difference in BMI between psoriasis cases and controls) (see Supporting Text 2 in S1 Appendix). Two-350 
sample MR analysis was also performed using the “MendelianRandomisation” R package [31] with 351 
summary results from GWAS studies for psoriasis [16] and from the GIANT BMI GWAS [14]. The one 352 
and two-sample MR estimates were meta-analysed using a fixed effect model, to give a final causal 353 
estimate. For the sake of interpretation, the estimates obtained were multiplied by 0.693 to represent 354 
the change in BMI per doubling in odds of psoriasis, as demonstrated by Gage et al [36]. 355 
Sensitivity analyses were performed with MR-Egger regression, weighted median and weighted MBE 356 
methods. A separate two-sample MR analysis was performed in the same manner, where psoriasis 357 
SNP-BMI association estimates were extracted from the more recent BMI meta-analysis [15]. 358 
Variants within the HLA region were not included in the genetic instrument due to the pleiotropic 359 
nature of the region. However, two-sample MR analysis was performed using the SNP rs13200483 360 
alone as an instrument which tags the HLA-C*06:02 allele and is strongly associated with psoriasis 361 
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[37]. SNP estimates were taken from the most recent psoriasis GWAS [16], and the GIANT BMI study 362 
published by Locke and colleagues [14]. 363 
 364 
All analyses were performed using R (www.r-project.org) unless otherwise stated. There was no 365 
formal pre-specified protocol for this study. The main analyses and sensitivity analyses described 366 
above were decided on beforehand. This is with the exception of the sensitivity analysis performed 367 
with the most recent BMI meta-analysis [15], in order to demonstrate use of the most current GWAS 368 
summary data for BMI. We also performed sensitivity analysis with a variant at the HLA-C*06:02 locus 369 
as recommended by the reviewers. One-sample MR analyses were also performed within UK Biobank, 370 
stratifying for psoriasis individuals who were self-reported, or defined by the HES data extract service 371 
in response to reviewers’ comments. Furthermore, publication bias was investigated for the meta-372 
analysis of previously reported studies for the relationship between BMI and psoriasis as suggested 373 
by the reviewers. 374 
 375 
RESULTS 376 
Literature review and meta-analysis 377 
We identified 56 studies reporting data on the relationship between psoriasis and BMI, obesity or 378 
being overweight (see Fig A in S1 Appendix). A total of 35 studies which compared mean BMI between 379 
psoriasis cases and controls (Fig 2, see Supporting Text 3 in S1 Appendix) were taken forward to be 380 
meta-analysed. The meta-analysis found a mean difference in BMI between psoriasis cases and 381 
controls of 1.26 kg/m2 (95% CI 1.02 to 1.51) amongst adults (69,704 psoriasis cases and 617,704 382 
controls) and 1.55 kg/m2 (95% CI 1.13 to 1.98) in children (844 psoriasis cases and 709 controls). The 383 
ages of paediatric psoriasis patients ranged from 5 to 18 years. Where stated, the majority of the 384 
studies had defined adults to be those aged 18 years and older. However, a number of studies had 385 
used the age threshold of 15 years [38–42], and one 17 years to define adulthood [43]. For both adults 386 
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and children, the observed difference in BMI is equivalent to a 9% increase in the odds of psoriasis per 387 
1 kg/m2 increase in BMI. Twenty-one other studies tested for an association between BMI or obesity 388 
traits and psoriasis using alternative models (see Table 7 in S1 Appendix). These all reported a positive 389 
association, including two studies which reported the odds of psoriasis in adults per 1 kg/m2 increase 390 
in BMI to be 1.09 (95% CI 1.04 to 1.16) [43]and 1.04 (95% CI 1.02 to 1.10) [38]. We detected very little 391 
evidence of publication bias in the meta-analysis (see Fig B in S1 Appendix). 392 
   393 
  394 
Fig 2. Observational association between BMI and psoriasis. 395 
Meta-analysis of mean difference in BMI (kg/m2) between psoriasis cases and controls. 396 
Mean difference (MD) of 1.26 kg/m2 in adults is equivalent to OR of 1.092. MD of 1.55 kg/m2 in 397 
children is equivalent to OR of 1.093. 398 
Genetic instruments 399 
The BMI GRS was strongly associated with BMI in UK Biobank (Beta=0.64; 95% CI 0.63 to 0.66, F-400 
statistic=7091, R2=1.8%) and HUNT (Beta=0.66; 95% CI 0.60 to 0.72, F-statistic=422, R2=2.3%) (see Fig 401 
C and Fig D in S1 Appendix), providing evidence in support of the strength of this instrument. We 402 
investigated the association between the BMI GRS and potential confounders of BMI. Some small 403 
effects on the confounders were seen, however the strength of association was minimal in comparison 404 
to the association with BMI. This was also true for the FTO variant alone, which is unlikely to have 405 
horizontal pleiotropic effects on these confounders (see Fig E and Fig F in S1 Appendix). The GRS 406 
derived for psoriasis was a good predictor of psoriasis in UK Biobank (OR=1.55; 95% CI 1.51 to 1.59, F-407 
statistic=6415, R2=2.1%) and HUNT (OR=1.41; 95% CI 1.33 to 1.50, F-statistic=340, R2=1.8%) datasets. 408 
  409 
Effect of BMI upon psoriasis 410 
Observational analysis  411 
Higher BMI was associated with increased risk of psoriasis in both the UK Biobank and HUNT datasets. 412 
Overall, 1 kg/m2 increase in BMI was associated with 4% higher odds of psoriasis (meta-analysis 413 
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OR=1.04; 95% CI 1.03 to 1.04; P=1.73x10-60) (Fig 3), slightly lower than that estimated from published 414 
literature. 415 
  416 
 417 
Fig 3. Effect of BMI upon psoriasis. 418 
Meta-analysis of observational and one-sample and two-sample MR causal estimates (using 419 
individual BMI SNPs as instrumental variables). Observational analysis in HUNT is restricted to 420 
individuals with complete information on potential confounders. One-sample MR was performed 421 
separately in UK Biobank and HUNT using individual-level data. Two-sample MR was performed with 422 
published GWAS summary-level data for BMI (Locke et al, 2015) and psoriasis (Tsoi et al, 2017). 423 
Estimates are given as change in odds per 1 kg/m2 increase in BMI. 424 
CI=confidence interval; MR=Mendelian Randomization. 425 
  426 
 427 
 428 
Mendelian Randomization 429 
MR performed with UK Biobank, HUNT and published GWAS data gave evidence that higher BMI 430 
increases the risk of psoriasis. The causal estimate from UK Biobank showed an ~8% increase in odds 431 
of psoriasis per 1 kg/m2 higher BMI (OR=1.08; 95% CI 1.04 to 1.13; P=8.75x10-5). Similar causal 432 
estimates were also found when stratifying by psoriasis cases who were self-reported and those 433 
defined with the HES data extract service (see Table 8 in S1 Appendix). In HUNT a ~7% increase was 434 
shown (OR=1.07; 95% CI 0.98 to 1.17; P=0.14). The two-sample estimate from published GWAS data 435 
[14] also provided evidence of higher psoriasis risk with increased BMI (OR=1.10, 95% CI 1.05 to 1.16; 436 
P=6.46x10-5) (Fig 3). Meta-analysis of both one-sample and two-sample estimates produced an overall 437 
causal estimate of 1.09 per 1 kg/m2 higher BMI (95% CI 1.06 to 1.12; P=4.67x10-9, I2 statistic=0.0%) (Fig 438 
3), remarkably consistent with the observational estimate from the meta-analysis of the published 439 
literature. This estimate suggests that, for example, an increase in BMI of 5 units from 25 to 30 would 440 
increase the risk of psoriasis by 53% (OR per 5 units higher BMI = exp(Beta per 1 unit higher BMI * 5). 441 
There was little evidence of pleiotropy in the MR-Egger regression analysis (UK Biobank 442 
intercept=0.00; 95% CI -0.01 to 0.01; P=0.63, HUNT intercept=0.00; 95% CI -0.02 to 0.02; P=0.96) and 443 
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the sensitivity analyses all gave similar estimates (see Fig G and Table 9 in S1 Appendix). In addition, 444 
when limiting the instrument to only the FTO SNP, a similar estimate (although with a wider 445 
confidence interval) was observed (OR=1.11; 95% CI 1.04 to 1.19; P=1.22x10-3) (see Fig H in S1 446 
Appendix). 447 
  448 
Two-sample MR analysis was also performed using the larger number of BMI SNP estimates most 449 
recently published [15]. This gave a similar estimate to the overall causal estimate obtained (OR=1.10; 450 
95% CI 1.06 to 1.13; P=1.59x10-4). 451 
  452 
Reverse MR analysis - genetic liability for psoriasis upon BMI 453 
The meta-analysis of UK Biobank, HUNT and the two-sample data found no strong evidence for a 454 
causal effect of the genetic risk of psoriasis on BMI (0.004 kg/m2 change in BMI per doubling odds of 455 
psoriasis, 95% CI -0.003 to 0.011, P=0.23) (Fig 4). Similarly, no strong evidence of a causal effect was 456 
found when performing two-sample MR analysis with the variant at HLA-C*06:02 (rs13200483) alone, 457 
(0.03 kg/m2 change in BMI per doubling odds of psoriasis, 95% CI -0.02 to 0.07, P=0.24). Such estimates 458 
may be prone to misinterpretation if there is any heterogeneity of the effect within different 459 
subpopulations (e.g. effect only in a subset of the population, such as those with psoriasis) [44]. 460 
However, we found no strong evidence for such heterogeneity when comparing BMI variance across 461 
levels of the psoriasis genetic score in UK Biobank. The meta-analysis of the one-sample UK Biobank 462 
and HUNT estimates also estimated the increase in BMI in psoriasis cases compared to controls to be 463 
0.27 kg/m2 (95% CI -2.02 to 2.55), by treating psoriasis as a linear variable in the analysis. As this 464 
estimate is much smaller than the observational estimate (1.26 kg/m2) and the forward direction MR 465 
estimate is extraordinarily consistent with the observational estimate, we conclude that the majority 466 
of the relationship is due to a causal effect of BMI on psoriasis, rather than the other way around. 467 
  468 
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   469 
Fig 4. Reverse direction MR analysis - genetic liability for psoriasis upon BMI. 470 
Meta-analysis of one-sample and two-sample MR estimates (using individual psoriasis SNPs as 471 
instrumental variables). One-sample MR was performed separately in UK Biobank and HUNT using 472 
individual-level data. Two-sample MR was performed with published GWAS summary-level data for 473 
BMI (Locke et al, 2015) and psoriasis (Tsoi et al, 2017). Estimates represent the change in BMI 474 
(kg/m2) per doubling odds of psoriasis. 475 
F-statistic = 6415, R2 = 2.1% (UK Biobank); F-statistic=340, R2=1.8% (HUNT). 476 
DISCUSSION 477 
The rising prevalence of psoriasis and obesity are important public health concerns [3,5,37,45]. We 478 
found evidence of increased BMI having a causal effect upon psoriasis and the estimated effect size 479 
is of a magnitude that is likely to be clinically significant (9% increased risk of psoriasis for 1 unit 480 
increase in BMI). Furthermore, the direction and magnitude of effect seen is notably consistent with 481 
that seen observationally and in previous literature. In the reverse direction, the estimate of 0.27 482 
kg/m2 suggests much less influence of psoriasis on an individual’s BMI. Overall, our results give 483 
evidence that the observational estimates in the literature are predominantly explained by a causal 484 
effect of BMI upon psoriasis and are not substantially impacted by unmeasured confounding, 485 
implying that excess adiposity is part of the reason for some individuals developing psoriasis.  486 
  487 
A key limitation of MR analysis is the possibility of pleiotropic mechanisms (from genetic instrument 488 
to outcome, not via the exposure) invalidating the method. We performed various sensitivity 489 
analyses to explore potential pleiotropic effects of the SNPs that make up the BMI instrument. When 490 
restricting the instrument to only the FTO variant, for which there is good understanding of the 491 
biological mechanism[35], we found the estimate from this analysis to be consistent with the 492 
estimate using all BMI SNPs. This suggests that the causal estimates seen are not predominantly 493 
driven by pleiotropic SNPs with alternative biological effects. This is supported by the MR-Egger 494 
regression intercepts which were centred around zero (indicating no directional pleiotropy amongst 495 
the included variants). 496 
  497 
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Our analysis has included a total of 753,421 individuals, including data from two of the biggest 498 
population-based studies currently available, and one of the largest published GWAS studies. We 499 
have applied both a one-sample and two-sample MR approach and the estimates from these 500 
analyses were meta-analysed to provide increased statistical power. The use of a strong genetic 501 
instrument for BMI provides an additional strength to this study.  502 
There are some likely limitations to this study. The data in our study included contemporaneous 503 
measurements of BMI but relied predominantly on patient report or recall for the ascertainment of 504 
psoriasis. This disease may follow an acute or chronic relapsing and remitting course. We do 505 
acknowledge that the possible misdiagnosis of psoriasis and mild sufferers remaining undiagnosed 506 
should be taken into account when interpreting the results of this study. Especially given the little 507 
overlap of psoriasis cases who are self-reported and also defined with the HES data extract service in 508 
UK Biobank (see Table 8 in S1 Appendix). Furthermore, the BMI SNPs used are a stronger instrument 509 
for adult BMI compared to childhood BMI [46]. In further work, the separate effects of visceral and 510 
subcutaneous fat may also be considered, as these are likely to have a greater impact upon 511 
inflammation compared to BMI alone. Our MR estimate is also limited in that it only informs on the 512 
lifetime impact of higher BMI on psoriasis, rather than the effect of a short-term intervention. 513 
Furthermore, as the cohorts studied were of European ancestry, this limits the ethnic variation of 514 
the study. 515 
 516 
Despite the large sample sizes included in the current study, the 1-sample estimates still have wide 517 
confidence intervals (due to the relative low number of cases in population-based cohorts). 518 
Nonetheless, the similarity of the causal estimates found when analysing UK Biobank, HUNT and 519 
previous GWAS data does increase confidence in our findings. As expected with a large sample size, 520 
we did observe some associations between the BMI GRS and potential confounders of BMI. 521 
However, we found these to be minimal in comparison to the strength of the association with raw 522 
BMI and therefore unlikely to be materially affecting the results. Nevertheless, it is important to 523 
22 
 
note the possible influences of unmeasured confounders, especially when utilising large data 524 
resources such as the UK Biobank.  525 
  526 
 527 
There are various possible mechanisms linking obesity with skin inflammation due to functional 528 
changes within adipose tissue as well as quantitative effects, such as the increased production of 529 
inflammatory cytokines from adipose tissue [47]. Excess skin adipose tissue results in pro-530 
inflammatory cytokine and hormone secretion. Cytokines such as TNFα and IL-6 are directly 531 
implicated in the pathology of psoriasis and are targets for some highly effective treatments [48,49]. 532 
Leptin can increase keratinocyte proliferation and pro-inflammatory protein secretion which are 533 
characteristics of psoriasis [50], whilst the secretion of adiponectin, which is putatively anti-534 
inflammatory [10] is reduced in the obese state. The skin of obese individuals shows features of 535 
impaired barrier function [51] whilst impairment in lymphatic function may delay the clearance of 536 
inflammatory mediators [47]. Other mechanisms remain possible; however these are weakly 537 
researched. Our results, supporting a causal relationship, suggest this area warrants further detailed 538 
work.   539 
 540 
Our findings suggest that approaches to the prevention and treatment of psoriasis might come from 541 
targeting adiposity levels in addition to the immune pathways in skin. Though our results propose 542 
that such interventions may be effective in prevention of psoriasis, they cannot determine that they 543 
would be effective at improving the disease course after onset. However, our findings do suggest 544 
that this is a promising area to explore, particularly with validation in a clinical trial setting to 545 
determine what magnitude of effect a particular intervention may have. This is also supported by 546 
previous reports of weight loss improving psoriatic skin and joint disease [52–54]. The concept of 547 
managing cardiovascular risk factors is already included in clinical guidelines for psoriasis, where 548 
although a strong observational relationship has been found between these two traits [55], there 549 
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has so far been little genetic or epigenetic overlap to support this [56]. In comparison, our findings 550 
provide evidence of causality for the observational relationship between higher BMI and psoriasis. 551 
Furthermore, our data provide even greater emphasis given the potential to yield substantial clinical 552 
benefits by the causal effect on skin disease. Importantly, our findings come at a time when weight 553 
loss strategies are improving in the community, with a variety of evidence-based interventions now 554 
emerging [57,58]. We believe the need for further trials of weight loss at different stages of psoriasis 555 
is strengthened by our work.  Although it has not been possible to investigate in the current study, 556 
analysing the causal effect of BMI upon severe psoriasis or various disease subtypes will also be of 557 
clinical value. We also note that the potential health implications of this study will be dependent 558 
upon elevated BMI in the community being amenable to intervention. 559 
  560 
In conclusion, our findings indicate a causal effect of BMI upon psoriasis which carries health 561 
implications. These results provide further evidence supporting the need to effectively manage 562 
obesity in the general population as well as in patients with psoriasis.  563 
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